← Leaderboards
Youcef M Rustum
Roswell Park Cancer Institute Corp
$3,055,559
Attributed
$3,055,559
Total exposure
5
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding mix
By agency
NIH$3,055,559 · 5
By mechanism
C06$2,000,000 · 3
G20$655,222 · 1
R21$400,337 · 1
Top collaborators
No co-investigators on record.
Most similar at Roswell Park Cancer Institute Corp
Same institution · by research overlap
- Wei Zheng$71,826,577
- Peter Demant$3,528,178
- Walter J Storkus$19,974,413
- Barbara A Foster$3,566,345
- Christine B. Ambrosone$40,409,261
Others in their field
Top investigators on “Building /Facility Design /Renovation”
- Charles L Bailey · George Mason University$25,000,000
- James R Gaines · University Of Hawaii At Manoa$24,999,553
- William M Pierce · University Of Louisville$21,945,188
- Benjamin F Payton · Tuskegee University$17,000,000
- Andrew A Lackner · Harvard University (Medical School)$16,048,259
- Deborah T. Kochevar · Tufts University Boston$15,596,515
Research focus
Building /Facility Design /RenovationBiomedical FacilityDna ReplicationNeoplasm /Cancer GeneticsApoptosisClinical ResearchClinical Trial Phase IColorectal NeoplasmsCombination ChemotherapyDiarrheaDosageDrug Adverse EffectDrug InteractionsEnzyme Induction /RepressionGastrointestinal Imaging /VisualizationHistopathologyHuman SubjectHuman Therapy EvaluationImmunocytochemistryIntestinal MucosaIrinotecanMonitoring DeviceNeoplasm /Cancer ChemotherapyNonsteroidal Antiinflammatory Agent
Grant awards (5)
IMPROVING ANIMAL RESOURCES FOR CANCER RESEARCH AT RPCI$655,222
G20 · FY2004 · RR
Irinotecan in Combination with Celecoxib: A phase I Stu*$400,337
R21 · FY2004 · CA
ROSWELL PARK DNA REPLICATION PROG FACIL: STEM CELL$666,680
C06 · FY2002 · RR
ROSWELL PARK DNA REPLICATION PROG FACIL: GENET SMOKING$666,660
C06 · FY2002 · RR
ROSWELL PARK DNA REPLICATION PROG FACIL: ANTITUMOR DRUG$666,660
C06 · FY2002 · RR